Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.30 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.30 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771220 | 0.89 | DDAH1 (0.33) | CYP2C9GAAALDH1A1DDAH1SARM1 | |
| SCHEMBL6477928 | 0.88 | CYP2C9 (0.39) | CYP2C9GAAALDH1A1DDAH1ENGASE | |
| SCHEMBL13008023 | 0.87 | CYP2C9 (0.37) | CYP2C9GAAALDH1A1DDAH1SARM1 | |
| SCHEMBL3770559 | 0.87 | CYP2C9 (0.37) | CYP2C9ALDH1A1DDAH1SARM1IDO2 | |
| SCHEMBL5760319 | 0.87 | CYP2C9 (0.38) | CYP2C9GAAALDH1A1DDAH1ENGASE | |
| SCHEMBL5763545 | 0.82 | CYP2C9 (0.37) | CYP2C9GAAALDH1A1DDAH1ENGASE | |
| SCHEMBL5762088 | 0.81 | CYP2C9 (0.36) | CYP2C9GAAALDH1A1DDAH1ENGASE | |
| SCHEMBL6531921 | 0.79 | CYP2C9 (0.35) | CYP2C9ALDH1A1DDAH1ENGASE | |
| SCHEMBL5368047 | 0.79 | CYP2C9 (0.36) | CYP2C9ALDH1A1DDAH1ENGASE | |
| SCHEMBL13008031 | 0.78 | PSEN1 (0.32) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| WO-2008036201-A1 | PRODRUGS OF PROTON PUMP INHIBITORS INCLUDING THE 1H-IMIDAZO[4,5-B] PYRIDINE MOIETY | ALEVIUM PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ABCB11, ATP6AP1, CYP4B1 | CYP2C9 44/4885GAA 406/4885ALDH1A1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.